Vasopressin Articles
FDA panel gives nod to Otsuka's tolvaptan
7 July 2008
EMEA accepts Otsuka's tolvaptan MAA
3 March 2008
Lixivaptan in Ph III hyponatremia and heart failure trial
25 February 2008
Ph IIa trial of Movetis' M0002 completes enrollment
14 January 2008
FDA accepts NDA for Otsuka's tolvaptan
7 January 2008
Vaprisol raises sodium levels in hyponatremia
5 November 2007
Otsuka's tolvaptan improves ADHF
2 April 2007
European cardiovascular market growth drivers identified
30 October 2006
Japan stock market week to January 9
16 January 2006
Fast-track for PDL/Orphan's terlipressin
25 April 2005
Sosei license urology drug from Otsuka
28 February 2005
FDA wants more safety data on conivaptan
13 December 2004
Sanofi-Synthelabo reveals R&D pipeline with nine compounds in Ph III
23 February 2004
Yamanouchi files conivaptan NDA
9 February 2004
Sanofi, Lilly to develop oxaliplatin in USA
20 April 1999
Sanofi-Synthelabo Merger Strong In Cardio, CNS
10 December 1998
Sanofi's Eloxatin Gearing Up For Global Roll-Out
30 June 1998
W-L To Stay Independent As Product Line Improves
30 April 1998
W-L To Stay Independent As Product Line Improves
24 April 1998
W-L Estimates 1998 EPS Growth Over 35%
23 April 1998
Launch Of Serenics Through Lilly Deal
19 June 1997
R-PR To launch Oral Diabetes Insipidus Drug
19 February 1996
Roussel-Uclaf Details Group Pipeline Plans
10 April 1995
1993 A GRIM YEAR FOR INDUSTRY, SAYS SANOFI
6 December 1993
YOSHITOMI - A NEW ANTIDEMENTIA DRUG
4 January 1993
SAVE STUDY CONFIRMS ACE INHIBITOR BENEFITS
7 September 1992
THERAPEUTIC PEPTIDE MARKET
6 July 1992
Showing 1-34 of 34 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
